Performance fatigability is an independent component of motor impairment and, therefore, a potential therapeutic target in adult patients with spinal muscular atrophy (SMA) who are still able to walk, according to a new study published in the scientific journal Muscle and Nerve. The authors also reported that treatment with nusinersen...